Market Cap | 4.91B | P/E | - | EPS this Y | 27.10% | Ern Qtrly Grth | - |
Income | -56.9M | Forward P/E | 11.52 | EPS next Y | 14.10% | 50D Avg Chg | 7.00% |
Sales | 4.63B | PEG | 1.28 | EPS past 5Y | -18.06% | 200D Avg Chg | 3.00% |
Dividend | 3.00% | Price/Book | 1.02 | EPS next 5Y | 10.00% | 52W High Chg | -17.00% |
Recommedations | 1.70 | Quick Ratio | 1.26 | Shares Outstanding | 135.40M | 52W Low Chg | 18.00% |
Insider Own | 0.95% | ROA | 1.48% | Shares Float | 134.66M | Beta | 0.82 |
Inst Own | 98.72% | ROE | -1.17% | Shares Shorted/Prior | 4.60M/4.57M | Price | 36.30 |
Gross Margin | 34.28% | Profit Margin | -1.46% | Avg. Volume | 1,186,327 | Target Price | 49.00 |
Oper. Margin | 5.58% | Earnings Date | Nov 6 | Volume | 868,674 | Change | -0.14% |
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in Ireland, the United States, France, Belgium, China, the United Kingdom, Germany, Switzerland, Austria, Italy, Australia, Greece, and Spain. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The Consumer Self-Care Americas segment develops, manufacture, and markets self-care products including upper respiratory, pain and sleep-aids, digestive health, nutrition, healthy lifestyle, skincare, women's health, and other products, as well as vitamins, minerals and supplements, and oral self-care in the United States and Canada. This segment offers its products under Burt's Bees, Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, and Steripod brands. Consumer Self-Care International segment comprises consumer self-care product categories outside the U.S. and Canada, including branded products in Europe and Australia, and store brand products in the United Kingdom and parts of Europe and Asia, which develops, manufactures, markets, and distributes consumer self-care brands through a network of drug and grocery store retailers, e-commerce stores, and para-pharmacies in more than 29 countries, primarily in Europe. In addition, the company offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
JP Morgan | Overweight | Aug 9, 23 |
Canaccord Genuity | Buy | Mar 7, 23 |
Raymond James | Outperform | Mar 6, 23 |
Raymond James | Outperform | Nov 9, 22 |
Argus Research | Buy | Sep 14, 22 |
Wells Fargo | Overweight | Sep 6, 22 |
Raymond James | Outperform | May 4, 22 |
Raymond James | Outperform | Nov 11, 21 |
Raymond James | Outperform | Oct 14, 21 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Manzone Albert | Director Director | Aug 15 | Option | 38.88 | 5,478 | 212,985 | 5,478 | 08/17/23 |
Ives Alison | EVP & Chief Scientif.. EVP & Chief Scientific Officer | Jul 07 | Option | 32.63 | 920 | 30,020 | 8,611 | 07/10/23 |
HANSON KYLE | EVP & General Counse.. EVP & General Counsel | Jul 07 | Option | 32.63 | 12,409 | 404,906 | 9,552 | 07/10/23 |
Parker Geoffrey M. | Director Director | Jun 13 | Buy | 33.0637 | 10,000 | 330,637 | 25,879 | 06/14/23 |
Andersen Svend | EVP & President CHCI EVP & President CHCI | May 23 | Buy | 33.4146 | 2,900 | 96,902 | 68,741 | 05/25/23 |
KESSLER MURRAY S | CEO CEO | May 11 | Sell | 35.7526 | 197,646 | 7,066,358 | 2,668 | 05/15/23 |
Dillard James E III | EVP & President CSCA EVP & President CSCA | Mar 10 | Sell | 35.701 | 9,000 | 321,309 | 25,130 | 03/14/23 |
Farrington Thomas | EVP and CIO EVP and CIO | Mar 13 | Sell | 35.58 | 3,723 | 132,464 | 2,823 | 03/14/23 |
Ives Alison | EVP & Chief Scientif.. EVP & Chief Scientific Officer | Mar 07 | Option | 37.71 | 1,746 | 65,842 | 8,201 | 03/09/23 |
Farrington Thomas | EVP and CIO EVP and CIO | Mar 06 | Option | 37.71 | 2,406 | 90,730 | 7,705 | 03/08/23 |
Parker Geoffrey M. | Director Director | Mar 06 | Buy | 38.054 | 5,000 | 190,270 | 15,879 | 03/07/23 |
Quinn Grainne | EVP, Chief Medical O.. EVP, Chief Medical Officer | Dec 16 | Sell | 31.65 | 2,368 | 74,947 | 9,118 | 12/20/22 |
Karaboutis Adriana | Director Director | May 17 | Option | 38.57 | 6,599 | 254,523 | 17,046 | 05/19/22 |
Doyle Katherine C. | Director Director | May 17 | Option | 38.57 | 6,599 | 254,523 | 9,530 | 05/19/22 |
O'Connor Donal | Director Director | May 17 | Option | 38.57 | 6,599 | 254,523 | 20,054 | 05/19/22 |
Mann Erica L | Director Director | May 17 | Option | 38.57 | 6,599 | 254,523 | 12,289 | 05/19/22 |
ASHFORD ORLANDO D | Director Director | May 17 | Option | 38.57 | 6,599 | 254,523 | 8,150 | 05/19/22 |
Samuels Theodore R. II | Director Director | May 17 | Option | 38.57 | 6,599 | 254,523 | 26,693 | 05/19/22 |
Alford Bradley A | Director Director | May 17 | Option | 38.57 | 6,599 | 254,523 | 30,577 | 05/19/22 |
Parker Geoffrey M. | Director Director | May 17 | Option | 38.57 | 6,599 | 254,523 | 14,829 | 05/19/22 |
KINDLER JEFFREY B | Director Director | May 17 | Option | 38.57 | 6,599 | 254,523 | 17,574 | 05/19/22 |
SILCOCK RAYMOND | EVP, Chief Financial.. EVP, Chief Financial Officer | Apr 05 | Option | 36.27 | 3,963 | 143,738 | 60,955 | 04/07/22 |
Farrington Thomas | EVP and CIO EVP and CIO | Mar 14 | Sell | 37.18 | 26,744 | 994,342 | 03/16/22 | |
Willis Robert | EVP & CHRO EVP & CHRO | Mar 04 | Option | 37.23 | 5,012 | 186,597 | 9,760 | 03/08/22 |
Janish Ronald Craig | EVP, Gbl Ops & SC &.. EVP, Gbl Ops & SC & CTO | Mar 04 | Option | 37.23 | 5,410 | 201,414 | 20,559 | 03/08/22 |
Janish Ronald Craig | EVP, Gbl Ops & SC &.. EVP, Gbl Ops & SC & CTO | Mar 04 | Sell | 36.73 | 3,954 | 145,230 | 15,686 | 03/08/22 |
Farrington Thomas | EVP and CIO EVP and CIO | Mar 04 | Option | 37.23 | 4,424 | 164,706 | 25,185 | 03/08/22 |
ASHFORD ORLANDO D | Director Director | Mar 04 | Option | 37.23 | 2,984 | 111,094 | 2,984 | 03/08/22 |
KINGMA TODD W | Executive VP, Genera.. Executive VP, General Counsel | Mar 04 | Option | 37.23 | 8,911 | 331,757 | 46,677 | 03/08/22 |
Dillard James E III | EVP & President CSCA EVP & President CSCA | Mar 04 | Option | 37.23 | 7,002 | 260,684 | 24,148 | 03/08/22 |
Quinn Grainne | EVP, Chief Medical O.. EVP, Chief Medical Officer | Mar 04 | Option | 37.23 | 3,862 | 143,782 | 12,310 | 03/08/22 |
KESSLER MURRAY S | CEO CEO | Mar 04 | Option | 37.23 | 49,328 | 1,836,481 | 127,489 | 03/08/22 |
SILCOCK RAYMOND | EVP, Chief Financial.. EVP, Chief Financial Officer | Mar 04 | Option | 37.23 | 8,502 | 316,529 | 58,796 | 03/08/22 |
Andersen Svend | EVP & President CHCI EVP & President CHCI | Mar 04 | Option | 37.23 | 8,911 | 331,757 | 41,372 | 03/08/22 |
Dillard James E III | EVP & President CSCA EVP & President CSCA | Feb 07 | Option | 36.95 | 4,297 | 158,774 | 14,900 | 02/09/22 |
KESSLER MURRAY S | CEO CEO | Mar 09 | Option | 41.04 | 30,446 | 1,249,504 | 49,164 | 03/09/21 |
Kochan Sharon | EVP & President Rx EVP & President Rx | Mar 09 | Option | 41.04 | 4,057 | 166,499 | 38,748 | 03/09/21 |
Sorota Richard S | EVP & President CSCA EVP & President CSCA | Mar 09 | Option | 41.04 | 2,540 | 104,242 | 10,053 | 03/09/21 |
Farrington Thomas | EVP and CIO EVP and CIO | Mar 09 | Option | 41.04 | 2,730 | 112,039 | 18,468 | 03/09/21 |
Dillard James E III | EVP, Chief Scientifi.. EVP, Chief Scientific Officer | Mar 09 | Option | 41.04 | 4,322 | 177,375 | 11,173 | 03/09/21 |
Willis Robert | EVP & CHRO EVP & CHRO | Mar 09 | Option | 41.24 | 2,780 | 114,647 | 4,788 | 03/09/21 |
Quinn Grainne | EVP, Chief Medical O.. EVP, Chief Medical Officer | Mar 09 | Option | 41.04 | 2,279 | 93,530 | 7,299 | 03/09/21 |
Janish Ronald Craig | EVP, Gbl Ops & SC &.. EVP, Gbl Ops & SC & CTO | Mar 09 | Option | 41.04 | 3,339 | 137,033 | 14,835 | 03/09/21 |